The potential for a novel chemotherapy approach

How prodrug technology can lead to improved delivery of potent chemotherapy in select tumour types

February 25, 2021

Moving On Up

We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat

October 29, 2020

ESMO20 Preview 1 – Key progress in biomarker development

A look at progress and new developments in cancer biomarker developments

September 9, 2020

A novel way to target KRAS mutant lung cancer

Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer

August 13, 2020

Looking for Signals in Cancer Immunometabolism

In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.

August 6, 2020

The brightest flame casts the darkest shadow

George Martin’s quote seems rather apt this morning as NextCure announced there was disappointing…

July 13, 2020

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

Important findings on the renal cell cancer front

There's a wealth of clinical and biomarker data to explore in RCC, which may have implications for prescribing changes in the near future

June 12, 2020

Solid tumour winners and losers at ASCO20

Highlights from several solid tumour trials in both early and late stage disease.

June 9, 2020

Hematology Winners and Losers at ASCO20

Which hematology products in development produced the best data at ASCO 2020? We took a look at the key studies in lymphomas and myelomas to find out.

June 4, 2020

A rock around the breast cancer clock

Highlights from various breast cancer trials and new pipeline developments

June 2, 2020

A false dawn in adjuvant EGFR mutant lung cancer? Dr Ross Camidge provides a critical review of ADAURA

Dr Ross Camidge provides a critical review of ADAURA trial of osimertinib in adjuvant EGFR mutant lung cancer presented at the 2020 ASCO annual meeting.

June 1, 2020

Reflections on bench to bedside progress

From bench to bedside has many twists and turns along the way - an update on a longitudinal story we have been following for 5 years

May 29, 2020
Gems from the ASCO Poster Halls

What to watch out for in Developmental Therapeutics at ASCO20

10 developmental therapeutics abstracts to watch out for at the ASCO 2020 virtual meeting

May 28, 2020

What’s new in advanced breast cancer?

There are a few new developments of note to consider from ESMO Breast this weekend plus more to come at ASCO20 on Friday

May 26, 2020

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer

May 21, 2020

ASCO20 Preview on the importance of modality in oncology R&D

Does modality matter in oncology drug development and if so, where?

May 19, 2020

Highlighting an under-rated clinical development at ASCO20

Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)

May 14, 2020

Is the Arvinas PROTAC Proof of the Pudding?

What do we learn from the initial data with novel PROTAC technology?

May 13, 2020

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020

New directions in adenosine axis targeting

A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview

May 7, 2020